Clinical trialNCT06692452WithdrawnPhase 2Interventional

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

SponsorEric Jacobsen, MDEnrollment0Angioimmunoblastic T-cell LymphomaEnteropathy-Associated T-Cell LymphomaLymphomaMonomorphic Epitheliotropic Intestinal T-Cell LymphomaPeripheral T Cell Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Eric Jacobsen, MD
Dana-Farber Cancer Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

No facility list is in our current data snapshot for this study. The registry record on ClinicalTrials.gov ↗ carries any published locations. Why? →

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 24 Dec 2024
Primary completion: 1 Oct 2027
Completion: 1 Oct 2032
Last update posted: 1 Apr 2026
Registered enrollment: 0
Registry id: NCT06692452

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.